Table 2.
Multivariate survival analyses of factors associated with disease‐free survival in the the Fudan University Shanghai Cancer Center cohort of patients with triple‐negative breast cancer
| HR (95% CI) | P‐value | |
|---|---|---|
| Age, years | ||
| <40 | Reference | ‐ |
| 41‐60 | 0.53 (0.25‐1.13) | .101 |
| >61 | 0.27 (0.09‐0.80) | .019 |
| Menopause | ||
| No | Reference | ‐ |
| Yes | 1.37 (0.79‐2.36) | .260 |
| Grade | ||
| II | Reference | ‐ |
| III | 0.86 (0.49‐1.48) | .577 |
| Tumor size | ||
| T1 | Reference | ‐ |
| T2 | 1.22 (0.72‐2.04) | .462 |
| T3 | 2.16 (0.72‐6.45) | .167 |
| Lymph nodes | ||
| Negative | Reference | ‐ |
| Positive | 2.31 (1.40‐3.81) | .001 |
| ER | ||
| Negative | Reference | ‐ |
| Positive | 0.92 (0.43‐2.00) | .840 |
| PR | ||
| Negative | Reference | ‐ |
| Positive | 0.44 (0.19‐1.00) | .051 |
| HER2 | ||
| Negative | Reference | ‐ |
| Positive | 0.52 (0.28‐0.92) | .018 |
| Chemotherapy | ||
| No | Reference | ‐ |
| Yes | 0.33 (0.13‐0.82) | .017 |
| Unknown | 0.81 (0.23‐2.84) | .744 |
| miR‐493 status | ||
| Low expression | Reference | ‐ |
| High expression | 0.51 (0.28‐0.92) | .026 |
‐, not applicable; CI, confidence interval; ER, estrogen receptor; FUSCC, Fudan University Shanghai Cancer Center; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; miR, microRNA; PR, progesterone receptor.